The immuno-inflammatory cascade

British Journal of Anaesthesia

Volumn 77, Issue 1, 1996, Pages 11-16

  Galley, H F ^a   Webster, N R ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Complications, infections; Immune response; Proteins, cytokines

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; INTERFERON; INTERLEUKIN DERIVATIVE; MAJOR HISTOCOMPATIBILITY ANTIGEN;

ANTIBODY RESPONSE; CELLULAR IMMUNITY; IMMUNE RESPONSE; INFLAMMATION; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; SEPSIS; T LYMPHOCYTE;

EID: 0029957701     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/77.1.11     Document Type: Article

References (24)

1. Ashkenazi A, Marsters SA, Capon DJ, Chamow SM, Figari IS, Pennica D, Goeddel DV, Palladino MA Jr, Smith DH. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proceeding of the National Academy of Sciences USA 1991; 88: 10535-10539.
2. Beutler B, Greenwald D, Hulmes JD. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985; 316: 552-554.
3. Cowley HC, Heaney D, Gearing A, Webster NR. Increased circulating adhesion molecule concentrations in patients with the systemic inflammatory response syndrome: a prospective cohort study. Critical Care Medicine 1994; 22: 651-657.
4. Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP. Interleukin 1 (IL-1) receptor antagonist binds to the 80kDa IL-1 receptor but does not initiate IL-1 signal transduction. Journal of Biological Chemistry 1991; 266: 10331-10336.
5. Farrar MA, Schreiber RD. The molecular biology of interferon-gamma. Annual Review of Immunology 1993; 11: 571-611.
6. Gerard C, Bruyns C, Marchant A, Abramowicz D, Vasndenabeele P, Delvaux A, Fiers W, Goldman M, Velu T. Interleukin 10 reduces the lethality of tumour necrosis factor and prevents lethality in experimental endotoxemia. Journal of Experimental Medicine 1993; 177: 547-550.
7. Goode HF, Webster NR. Free radicals and antioxidants in sepsis. Critical Care Medicine 1993; 21: 1770-1776.
8. Han J, Thompson P, Beutler B. Dexamethasone and pentoxyfylline inhibit endotoxin induced cachectin/TNF synthesis at separate points of the signalling pathway. Journal of Experimental Medicine 1990; 172: 391-394.
9. Horuk R.The interleukin 8 receptor family: from chemokines to malaria. Immunology Today 1994; 15: 169-173.
10. Klein B, Braily H. Cytokine binding proteins: stimulating antagonists. Immunology Today 1995; 16: 216-220.
11. Koltai M, Hosford D, Guinot P, Esanu A, Braquet P. PAF: a review of its effects, antagonists and possible future clinical implications. Drugs 1991; 42: Part I 9-29, Part II 174-204.
12. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil, SS, Sobel RA, Wiener HL, Nabavi M, Glimcher LH. B7-1 and B7-2 co-stimulatory molecules activate differentially the Th1/Th2 developmental pathways. Cell 1995; 80: 707-718.
13. Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, Kaghad M, Labit C, Leplatoit P, Liauzun P, Miloux B. Interleukin 13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993; 362: 248-250.
14. Nelson BH, Lord JD, Greenberg PD. Cytoplasmic domains of the interleukin 2 receptor beta and gamma chains mediate the signal for T-cell proliferation. Nature 1994; 369: 333-336.
15. Ohlsson K, Bjork P, Bergenfeldt M. Interleukin 1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348: 550-552.
16. Perlmutter DH, Dinarello CA, Punsal PI, Cohen HR. Cachectin/tumour necrosis factor regulated hepatic acute phase gene expression. Journal of Clinical Investigation 1986; 78: 1349-1354.
17. Pimental E. Handbook of Growth Factors, Volume III, Boca Raton: CRC Press, 1994.
18. Redi H, Schlag G, Marzi I. Leucocyte endothelial interactions in trauma and sepsis. In: Lamy M, Thijs LG, eds. Mediators of Sepsis, Berlin: Springer-Verlag, 1992; 124-135.
19. Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochemical Journal 1994; 300: 281-290.
20. Tartaglia LA, Pennica D, Goeddel DV. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signalling by the 55-kDa TNF receptor. Journal of Biological Chemistry 1993; 268: 18542-18548.
21. Thijs LG, Hack CE. Role of the complement cascade in severe sepsis. In: Lamy M, Thijs LG, eds. Mediators of Sepsis. Berlin: Springer-Verlag, 1992; 78-98 .
22. Tracey K, Fong Y, Hesse DG. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-664.
23. VanZee KJ, Kohno T, Fischer E, Rock CS, Moldawer L, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proceedings of the National Academy of Sciences USA 1992; 89: 4845-4849.
24. Webster NR on behalf of the Intersept Study Group. Intersept: An international efficacy and safety study of monoclonal antibody (Mab) to human tumour necrosis factor in patients with the sepsis syndrome. Clinical Intensive Care 1995; 6: S81.